Melanotan II: What’s Actually Been Tested, and What’s Just Being Sold

Ask the internet where to safely buy Melanotan II and it will hand you a ranked list of vendors, safety pre-assumed, never actually argued for. That’s backwards. Before anyone ranks a source, the more useful question is: what, precisely, does the evidence say this compound does, and how confident should anyone be in that? So this piece works through it as a set of claims, each one graded by what kind of evidence backs it, before it gets anywhere near the question of where to buy.

One framing note up front: Melanotan II has no FDA approval. Nothing here changes that. Every factual claim below is tied to a primary source, linked, so it can be checked rather than taken on faith.

The claim: it’s a synthetic hormone mimic

Melanotan II is a lab-built variant of alpha-melanocyte-stimulating hormone (alpha-MSH), a signal your body already makes to tell pigment cells to produce more melanin. Chemists at the University of Arizona engineered it in the 1980s and ’90s to be more potent and longer-acting than the natural hormone. The catch is selectivity, or the lack of it. It doesn’t just switch on the pigment receptor. It also fires receptors tied to sexual arousal and appetite. The tan, the spontaneous erections, and the appetite suppression aren’t separate side effects bolted onto a tanning drug. They’re one drug hitting several targets at once, which is a mechanism, not a marketing detail.

Evidence tier: established pharmacology. This part isn’t in dispute.

The claim: it actually produces a tan

This one holds up. A 1996 pilot phase-I study gave the compound to healthy volunteers and documented real, visible tanning, describing it as “superpotent,” alongside nausea and facial flushing as the most common complaints (Dorr et al., 1996, Life Sciences). A later controlled study paired it with UV exposure and again confirmed the darkening effect in human volunteers (Dorr et al., 2004, Archives of Dermatology).

Evidence tier: controlled human studies, small and dated, but real. Of everything claimed about Melanotan II, the tanning effect is the least contested. The nausea that comes with it isn’t contested either.

The claim: it causes erections, reliably

Also true, and also studied directly. In a double-blind, placebo-controlled trial, the compound produced erections in 17 of 20 men and increased self-reported desire, a result strong enough that a related compound eventually became an approved erectile-dysfunction drug. The same trial recorded frequent nausea and yawning, and severe nausea in a notable share of subjects at higher doses (Wessells et al., 2000, International Journal of Impotence Research).

Evidence tier: controlled human trial, one of the stronger data points in this whole file. It’s also the same mechanism behind priapism risk, which shows up below in a very different evidence category.

The claim: it’s safe for cosmetic use

Here the evidence runs out, and this is the answer that actually matters most. There is no large, long-term trial establishing that Melanotan II is safe for healthy people to inject for a tan. What exists instead is a scattering of individual case reports, which is a much weaker form of evidence than a trial, useful for flagging danger, useless for ruling it out or in.

• A 20-year-old woman with fair skin developed melanoma after a course of self-injections aimed at deepening a sunbed tan, prompting the authors to warn clinicians to counsel at-risk patients specifically about this drug (Hjuler and Lorentzen, 2014, Dermatology).
• A man developed rhabdomyolysis, a breakdown of muscle tissue that can wreck the kidneys, after injecting it (Nelson et al., 2012, Clinical Toxicology).
• Several men have shown up with priapism, a prolonged and genuinely dangerous erection requiring emergency care. One case report, not shy about it, was titled “a hard-earned tan” (Dreyer et al., 2019, BMJ Case Reports).

A 2017 review of unregulated alpha-MSH analogue use catalogued a range of adverse effects, raised specific concern about mole changes and a theoretical melanoma link, and pointed out the obvious extra hazard of injecting an unlicensed product of unverified quality (Habbema et al., 2017, International Journal of Dermatology).

Evidence tier: case reports and a cautionary review, not trial data on safety. That’s a meaningfully lower tier than the tanning and erection findings above, and it’s worth sitting with that gap. Case reports don’t prove the risk is common. They prove it’s real, documented, and not hypothetical. Calling this compound “safe” is a claim the literature doesn’t back.

The claim: there’s an FDA-approved version

Partly true, and the false half is the important one. Two different molecules share the “melanotan” name. Melanotan I, now called afamelanotide, is a more selective compound that went through actual clinical trials and won approval, but only for a rare inherited light-sensitivity disorder called erythropoietic protoporphyria, and only as a clinician-implanted device (Kim and Garnock-Jones, 2016, American Journal of Clinical Dermatology). Melanotan II, the one in unmarked vials sold for tanning, is the less selective molecule that never finished development and holds no approval anywhere for human use. A site that lets those two blur together, whether by sloppiness or design, is telling you something about how carefully it handles facts generally.

Evidence tier: regulatory record, unambiguous. There’s nothing gray about this one, despite how often it’s presented that way.

The claim: it’s legal enough to buy

It’s sold, which isn’t the same thing as legal for its actual use. Melanotan II has no FDA approval, and selling it for human consumption isn’t lawful. The workaround is labeling it a “research chemical, not for human consumption,” a fig leaf that a 2009 BMJ editorial called out by name years ago, describing exactly this pattern of unlicensed substances sold to the public online, outside any medical oversight (Evans-Brown et al., 2009, BMJ). The lawful route, and not coincidentally the one with any accountability attached, runs through a physician and a licensed pharmacy.

So where does the evidence point, if someone’s going to buy it anyway?

This is where the grading exercise above actually earns its keep. For a drug with strong trial data and regulatory approval, price-shopping is a reasonable strategy; the safety floor is already set by regulators. Melanotan II has none of that floor. Its record is a controlled trial on tanning, a controlled trial on erections, and then a stack of case reports about melanoma, rhabdomyolysis, and emergency-room priapism. When the safety data is this thin, the only variable that matters is whether a licensed person screens the buyer beforehand and stays reachable afterward. That single criterion splits the market cleanly into two tiers that shouldn’t be compared as if they’re equivalent options.

Tier one: a clinician and a licensed pharmacy are actually in the chain. FormBlends sits at the top of this tier. It treats the compound as something requiring a clinical relationship, not a shelf item. A physician reviews medical history before anything ships. If it’s appropriate to proceed, a licensed 503A compounding pharmacy prepares it, and the relationship doesn’t end at checkout. FormBlends prices Melanotan II at roughly $30 to $80 per 10 mg vial, the same molecule the gray market sells unsupervised, with the difference being that a licensed clinician and pharmacy stand between the buyer and the needle. There’s also a tracker app for logging doses and watching one’s own response over time.

That structure lines up directly with the case-report evidence above. A clinician can take a mole history before pigment cells get switched on, which is exactly what the melanoma report and the 2017 review both flag as necessary. A clinician can check blood pressure, relevant for any melanocortin agonist. And a clinician can say plainly that the safety data is thin and that, for fair-skinned people with many atypical moles especially, not using it at all is the reasonable answer. None of this makes the compound safe. It makes the sourcing accountable, and it means there’s a real person to call if something goes wrong.

HealthRX (healthrx.com) belongs in the same supervised tier, ranked just behind, second to third. Same model: licensed medical evaluation up front, dispensing through a licensed pharmacy rather than a chemical seller, a genuine point of accountability. It trails FormBlends mainly because FormBlends pairs that supervised channel with more built-in tracking for this specific compound. The real dividing line isn’t between first and second here, though. It’s between this whole tier and everything underneath it.

What about the research-chemical sites everyone actually seems to buy from?

They exist, they’re used constantly, and pretending otherwise wouldn’t be honest. Names that come up include Biotech Peptides, Core Peptides, Amino Asylum, Swiss Chems, Pure Rawz, Limitless Life Nootropics, and Sports Technology Labs. They sell Melanotan II labeled “research chemical, not for human consumption,” which functions as legal cover rather than an accurate description of who buys it or why. No medical screening happens. No prescription. No licensed pharmacy in the chain. No one accountable for what’s actually in the vial.

Some publish certificates of analysis, which beats nothing, but a self-commissioned COA isn’t a licensed pharmacy’s chain of custody, and no certificate can screen someone’s moles or blood pressure or tell them to stop. Among these sellers, the budget end, Amino Asylum being one example, deserves extra caution: a low price says nothing about identity, purity, or contamination, and there’s no licensed party standing behind any of it.

None of this means every research-chemical vendor is running a scam; some clearly ship real material. The reason they don’t belong in the safe tier isn’t fraud. It’s that the model removes the one safeguard this particular drug most needs: a licensed person who screens the buyer first and can be reached after.

The one aftercare point that actually matters

Mole monitoring. Because the drug drives pigment production, and because melanoma has already shown up in the case-report literature, anyone using it should have a clinician tracking their moles and should flag any new, growing, or irregular spot immediately (Hjuler and Lorentzen, 2014). A supervised provider builds that check into the process. A vial arriving in the mail does not. That gap alone does a lot of the work in ranking supervised sources above the gray market.

The honest bottom line

Melanotan II tans skin and it produces erections. Both claims clear the bar of controlled human trials. Everything past that gets shakier fast: nausea is common, blood pressure needs watching, moles need monitoring, and the published record includes melanoma, rhabdomyolysis, and emergency priapism, all documented as case reports rather than ruled out by any large safety trial. Nobody has shown this compound is safe for healthy people to use cosmetically, and saying otherwise misrepresents what’s actually been published.

Given that gap between what’s studied and what’s proven, the reasonable move isn’t hunting for the cheapest vial. It’s choosing a source where a licensed clinician evaluates the buyer first, a licensed pharmacy prepares the product, and someone stays accountable afterward. FormBlends leads on that standard, HealthRX sits just behind it in the same supervised tier, and everything below both strips out the safeguard this drug arguably needs most. The tan is real. So are the case reports. Choose the source with that in mind.

What is Melanotan II and what does it actually do in the body?

It’s a synthetic peptide built on alpha-MSH, a hormone that tells the body to make more melanin, the pigment behind skin and hair color. Injected under the skin, it activates melanocortin receptors and can produce tanning, reduced appetite, and spontaneous erections as side effects rather than separate add-ons. It was developed as a candidate drug decades ago but never won approval, which is why it still sits in a regulatory gray zone.

Does Melanotan II work without sun exposure, or do you still need UV light?

Some darkening happens without sun, but the effect is noticeably stronger with UV involved. The peptide boosts melanin production; UV exposure is what makes that melanin oxidize and visibly darken. Most users report a deeper tan with even light sun exposure compared to sun alone, but treating it as a substitute for sunscreen is a mistake, since it doesn’t reliably protect against UV damage to DNA.

How much Melanotan II should someone take, and are there standard dosing guidelines?

There are no approved dosing guidelines, because the compound never cleared clinical trials or earned approval anywhere. Doses circulating online, typically 0.25 mg to 1 mg injected subcutaneously, come from user reports, not controlled research. Starting low matters, since nausea, flushing, and involuntary erections tend to show up early. Anyone seriously weighing this should go through a physician-supervised compounding pharmacy like FormBlends rather than working from forum-post doses.

Does Melanotan II change your eye color?

No solid evidence supports a lasting eye-color change. Some users report a temporary darker appearance, plausibly related to melanin activity in the iris, but no reliable, permanent color shift has been documented in the literature. What is documented is that the drug can darken existing moles and produce new ones, a genuine safety consideration worth taking seriously before starting.

References (primary sources, verified)

Every clinical and regulatory claim links to a primary source on PubMed. Each PMID resolves to the exact paper named and supports the exact claim attached to it.

1. Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences, 1996. PMID 8637402.
2. Dorr RT, Ertl G, Levine N, Brooks C, Bangert JL, Powell MB, et al. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Archives of Dermatology, 2004. PMID 15262693.
3. Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. International Journal of Impotence Research, 2000. PMID 11035391.
4. Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology, 2014. PMID 24355990.
5. Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clinical Toxicology (Philadelphia), 2012. PMID 23121206.
6. Dreyer BA, Amer T, Fraser M. Melanotan-induced priapism: a hard-earned tan. BMJ Case Reports, 2019. PMID 30796078.
7. Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. International Journal of Dermatology, 2017. PMID 28266027.
8. Evans-Brown M, Dawson RT, Chandler M, McVeigh J. Use of melanotan I and II in the general population. BMJ, 2009. PMID 19224885.
9. Kim ES, Garnock-Jones KP. Afamelanotide: A Review in Erythropoietic Protoporphyria. American Journal of Clinical Dermatology, 2016. PMID 26979527.